Performance characteristics of selected immunoassays for preliminary test of 3,4-methylenedioxymethamphetamine, methamphetamine, and related drugs in urine specimens.
Eight commercially available immunoassays for amphetamines (DRI Amphetamines, CEDIA DAU Amphetamines-Semiquantitative, EMIT d.a.u. Monoclonal Amphetamine/Methamphetamine, Synchron CX Systems AMPH, TDx/TDxFLx Amphetamine/Methamphetamine II, CEDIA Amphetamines/Ecstasy, COBAS INTEGRA Amphetamines, and Abuscreen((R)) OnLine HS Amphetamine/MDMA) are evaluated for their effectiveness in serving as the preliminary test methodology for the analysis of 3,4-methylenedioxymethamphetamine/3,4-methylenedioxyamphetamine (MDMA/MDA) and methamphetamine/amphetamine (MA/AM). Standard solutions (in urine matrix) of MDMA, MDA, MA, and AM are used to determine these immunoassays' reactivities (or cross-reactivities) toward these compounds of interest. Case specimens containing MDMA/MDA and MA/AM are also used to study the correlations of the apparent immunoassay MDMA (or MA) concentrations and the gas chromatographic-mass spectrometric concentrations of these compounds. Data resulting from this study suggest that CEDIA Amphetamines/Ecstasy can best predict the concentrations of MDMA and MA in case specimens and can also detect the presence of MDMA at low levels, whereas Abuscreen OnLine HS Amphetamine/MDMA can detect both MDMA and MA at low concentrations.
Hsu
Jui
J
National Bureau of Controlled Drugs, Department of Health, Taipei, Taiwan.
Liu
Chiareiy
C
Liu
C P
CP
Tsay
Wen-Ing
WI
Li
Jih-Heng
JH
Lin
Dong-Liang
DL
Liu
Ray H
RH
D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D008694:Methamphetamine / Q000652:urine*; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000652:urine*; D012015:Reference Standards; D012680:Sensitivity and Specificity; D013048:Specimen Handling; D015813:Substance Abuse Detection / Q000379:methods*
D008694:Methamphetamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine